iPhone | iPad
Android
Huawei
The prime minister understands the level of hurt in the country: Education Secretary
coronavirus21 hours ago
KT APPDOWNLOAD
Covid-19: Covaxin booster dose neutralises Delta, Omicron variants, says Bharat Biotech
The findings suggest that a booster dose has the potential to reduce disease severity and hospitalisations
Reuters file
Hyderabad-based Bharat Biotech on Wednesday claimed that its Covid-19 vaccine Covaxin can neutralise both the Delta and Omicron variants.
In a statement, Bharat Biotech said: “Results from a study conducted at Emory University demonstrating that sera from subjects who received a booster dose of Covaxin (BBV152) six months after getting a primary two-dose series of Covaxin, neutralized the SARS-CoV-2 Omicron and Delta variants.”
It also mentioned that earlier studies demonstrated the neutralizing potential of Covaxin against SARS-CoV-2 Variants of Concern Alpha, Beta, Delta, Zeta and Kappa.
The study will be published on the pre-print server, medRXiv, shortly. Sera samples from individuals who received a booster of Covaxin were observed to be effective in neutralising Omicron and Delta variants on a live virus neutralization assay.
The Hyderabad-based company claimed that the neutralisation activity of Covaxin boosted sera was comparable to what has been observed in mRNA vaccine-boosted sera against the Omicron variant and found more than 90 per cent of all individuals boosted with Covaxin showed neutralizing antibodies.
"All participants received an initial two-dose schedule of Covaxin on Day 0 and Day 28. As the dominant Covid-19 variant throughout the world, Omicron poses a serious public health concern,” said Mehul Suthar, PhD Assistant Professor, Emory Vaccine Centre who led the laboratory analysis.
Data from this preliminary analysis show individuals receiving a booster dose of Covaxin have a significant immune response to both the Omicron and Delta variants. These findings suggest that a booster dose has the potential to reduce disease severity and hospitalisations, said the statement.
ALSO READ:
“We are in a continuous state of innovation and product development for Covaxin. The positive neutralisation responses against the Omicron and Delta variants validate our hypothesis of a multi-epitope vaccine generating both humoral and cell-mediated immune responses. Our goals of developing a global vaccine against Covid-19 have been achieved with the use of Covasxin as a universal vaccine for adults and children,” said Dr Krishna Ella, chairman and managing director of Bharat Biotech.
“The global impact of Omicron shows us that the fight against Covid-19 continues, and we are encouraged that these data demonstrate the value of Covaxin as a primary and booster vaccine. These results show how a broad-spectrum vaccine has the potential ability to address ever-shifting public health challenges such as new variants and mutations,” said Dr Shankar Musunuri, chairman, CEO and co-founder, Ocugen, Inc.
More news from coronavirus
If given emergency-use approval, this would be the country's first mRNA Covid-19 vaccine like the ones developed by Pfizer and Moderna
coronavirus21 hours ago
The bank said Horta-Osorio resigned following an investigation commissioned by the board.
coronavirus1 day ago
Many local governments have already advised residents not to leave town unnecessarily trips during the holiday.
coronavirus1 day ago
The Telegraph reports UK Prime Minister Boris Johnson wants to permanently revoke emergency Covid-19 laws
coronavirus1 day ago
The new law will require people to have a certificate of vaccination to enter public places like restaurants, cafes, cinemas and long-distance trains
coronavirus1 day ago
Britain has a backlog of around 5.9 million people awaiting cancer screenings, scheduled surgeries and other planned care
coronavirus1 day ago
All security measures along with thermal scanning of students should be ensured before vaccination
coronavirus1 day ago